Mimedx Group, Inc. (MDXG) · Oct 28, 2026 · Earnings
Miss — Revenue $62M vs ~$68.6M consensus
MiMedx earnings missed on revenue as Medicare-driven wound-care disruption persisted, though surgical growth and cost cuts restored positive adjusted EBITDA.
MiMedx is trying to shift its growth engine toward surgical placental-tissue products while absorbing a major Medicare reimbursement reset in wound care and awaiting regulatory clearance for its Sanara acquisition. The quarter shows that transition is working operationally, but not yet enough to offset the wound-care drag.
Revenue missed the market’s bar. Q3 net sales were $62 million, below the published consensus of roughly $68.6 million, and down from $64 million in Q2. The shortfall reflects continued pressure in wound care and a softer U.S. surgical market, rather than a collapse in surgical demand. (Q3:26 Net Sales Summary)
| Metric | Q3 2026 | Comparison |
|---|---|---|
| Net sales | $62M | ~$68.6M consensus; $64M in Q2 2026 |
| Surgical net sales | $40M | +9% year over year; 64% of total |
| Wound net sales | $22M | 36% of total |
| GAAP net income | $(8.7)M | $(16.7)M swing versus $16.7M profit in Q3 2025 |
| Adjusted EBITDA | $2.1M | $35.0M in Q3 2025; 3.3% margin vs. 30.7% |
| Adjusted EPS | $(0.01) | $0.15 in Q3 2025 |
| 2026 net sales outlook | $250M–$260M | Reaffirmed in the filing |
The underlying surgical transition is gaining traction. Surgical sales reached $40 million, with mid-teens volume growth despite soft overall U.S. procedure volumes. HELIOGEN and the broader particulate portfolio are carrying momentum, while AMNIOFIX, AMNIOEFFECT, and G4Derm Plus add product breadth. The filing says, “Mid teens Surgical volume growth in Q3:26” 〔0〕 (Q3:26 Surgical Net Sales).
Wound care remains the central earnings problem. Wound sales were $22 million, and the January 1 Medicare reimbursement reset continues to disrupt the market. The better signal is that wound-care-center volumes rose 7% sequentially and more than 20% year over year, suggesting MiMedx is benefiting as activity migrates away from mobile practices; the weaker signal is that this recovery has not yet translated into enough company-wide profit. “Wound volumes up sequentially and year-over-year in Wound Care Centers.” 〔1〕 (Q3:26 Wound Net Sales)
Profitability improved sequentially, but the quality of the rebound is limited. Adjusted EBITDA returned to $2.1 million from negative territory in Q2, helped by cost reductions and manufacturing efficiencies, while gross margin recovered to 80%. But adjusted EBITDA was still sharply below the prior-year $35.0 million, and GAAP net loss was $8.7 million. The improvement is therefore a stabilization signal, not a return to the prior earnings profile. (Adjusted EBITDA - QTD; Q3:26 P&L Summary)
The filing adds several strategic positives, but they do not erase the earnings miss. A federal court vacated the FDA’s AXIOFILL classification decisions and remanded them for reconsideration, while a patent settlement is expected to provide $25 million in five annual $5 million installments. Those developments improve legal and cash-flow optionality, but neither is an immediate substitute for recurring sales. “The Court vacated FDA’s determination that AXIOFILL is not a Section 361 HCT/P because it is more than minimally manipulated.” 〔2〕 (Favorable Federal Court Ruling in FDA Litigation for AXIOFILL®)
Sanara remains a delayed growth lever rather than a current contribution. The FTC’s additional review was already disclosed on October 15, so this presentation mostly confirms that the deal remains pending rather than providing new closing visibility. MiMedx says it remains committed, but the $300 million financing is contingent on closing and carries a ticking fee. “We remain fully committed to the Sanara combination.” 〔3〕 (Sanara Transaction Undergoing Additional FTC Review)
Bottom line: The quarter missed expectations because wound-care reimbursement damage still outweighs surgical growth. MiMedx is rebuilding margins and proving the surgical strategy can grow, but the business has not yet converted that growth into a durable earnings recovery.
FTC resolution on the Sanara merger
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!